Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects

Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency. Subjects with acute anxiety symptoms (Hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. A check-up is made at D0, then the subjects begin the treatment (0.5mg risperidone). The same check-up is carried out on the following day (D1). The subjects fulfil a last check-up 12 week after the beginning of treatment (W12). During the D1-W12, the psychiatrist may changes the treatment.

Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency. Subjects with acute anxiety symptoms (Hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. After acceptation, the fulfil questionnaires (MINI, PCL-s-V) then they interacts with test on computers (PVT, 2nBack, Iowa gambling task) and give saliva and receive an actimetric watch (D0). They begin the treatment on the evening (0.5mg risperidone/day). The following day, they come back to hospital and they fulfil the same tests, questionnaires and samples (D1). 12 week after, they come again to hospital to fulfil the same tests, questionnaires and samples (W12). Between D1 and S12, the psychiatrist may change the treatment, adding other treatment or modifying risperidone treatment (increasing dosage up to 2mg/day or removing it).

All subjects are under 0.5mg risperidone (one group). Accordin to their response to treatment (responder vs. non responder) the 2 experimental groups will be created.

The 2 arms will be created according to the early response to risperidone (responder vs. non responder)

The 2 arms will be created according to the early response to risperidone (responder vs. non responder)

Inclusion Criteria: anxiety (score above 11 at anxiety scale of HADs) To have a prescription for 0.5 mg risperidone/day To give the consent To have a social protection To be adult (18-50 years) Exclusion Criteria: Psychiatric antecedents any treatment for mental disease (antidepressant, anxiolytics, etc.) Ongoing neurological pathologies Scheduled surgery addiction pregancy known intolerance to risperidone participation to another biomedical study